meto
Peptide

5-Amino-1MQ

A small-molecule NNMT inhibitor that increases cellular NAD+ and β-hydroxybutyrate — investigational for metabolic health and fat-loss support.

Definition

5-Amino-1MQ is a nicotinamide-N-methyltransferase (NNMT) inhibitor — technically a small molecule rather than a peptide, but frequently stocked alongside peptides. NNMT inhibition preserves NAD+ and raises β-hydroxybutyrate, a ketone body with metabolic-signalling effects. Preclinical data is promising for fat loss, metabolic resilience and muscle preservation; human clinical data is early.

How Meto uses it.

Considered at Meto case-by-case as a research-forward adjunct for members with specific metabolic goals. Evidence base is preclinical-leaning; framed as a considered addition rather than a first-line choice.

Safety notes

  • Human clinical evidence is early
  • Avoid in pregnancy and lactation
  • No significant drug-drug interactions documented to date

Not a complete list — your clinician reviews your full history, labs and medications during intake. Nothing here replaces that.

$149 panel.
A clinician reads it in 24 hours.

Order the Peptide Readiness Panel, draw at a Quest or LabCorp near you, and your clinician sends back a matched protocol with a confidence score.